Literature DB >> 29788207

Potentiating Hsp104 activity via phosphomimetic mutations in the middle domain.

Amber Tariq1, JiaBei Lin1, Megan M Noll1, Mariana P Torrente1, Korrie L Mack1,2, Oscar Hernandez Murillo1, Meredith E Jackrel1, James Shorter1.   

Abstract

Hsp104 is a hexameric AAA + ATPase and protein disaggregase found in yeast, which can be potentiated via mutations in its middle domain (MD) to counter toxic phase separation by TDP-43, FUS and α-synuclein connected to devastating neurodegenerative disorders. Subtle missense mutations in the Hsp104 MD can enhance activity, indicating that post-translational modification of specific MD residues might also potentiate Hsp104. Indeed, several serine and threonine residues throughout Hsp104 can be phosphorylated in vivo. Here, we introduce phosphomimetic aspartate or glutamate residues at these positions and assess Hsp104 activity. Remarkably, phosphomimetic T499D/E and S535D/E mutations in the MD enable Hsp104 to counter TDP-43, FUS and α-synuclein aggregation and toxicity in yeast, whereas T499A/V/I and S535A do not. Moreover, Hsp104T499E and Hsp104S535E exhibit enhanced ATPase activity and Hsp70-independent disaggregase activity in vitro. We suggest that phosphorylation of T499 or S535 may elicit enhanced Hsp104 disaggregase activity in a reversible and regulated manner.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29788207      PMCID: PMC6454557          DOI: 10.1093/femsyr/foy042

Source DB:  PubMed          Journal:  FEMS Yeast Res        ISSN: 1567-1356            Impact factor:   2.796


  142 in total

1.  Defining a pathway of communication from the C-terminal peptide binding domain to the N-terminal ATPase domain in a AAA protein.

Authors:  Anil G Cashikar; Eric C Schirmer; Douglas A Hattendorf; John R Glover; Melarkode S Ramakrishnan; Danielle M Ware; Susan L Lindquist
Journal:  Mol Cell       Date:  2002-04       Impact factor: 17.970

2.  A yeast prion provides a mechanism for genetic variation and phenotypic diversity.

Authors:  H L True; S L Lindquist
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

3.  alpha-Synuclein locus triplication causes Parkinson's disease.

Authors:  A B Singleton; M Farrer; J Johnson; A Singleton; S Hague; J Kachergus; M Hulihan; T Peuralinna; A Dutra; R Nussbaum; S Lincoln; A Crawley; M Hanson; D Maraganore; C Adler; M R Cookson; M Muenter; M Baptista; D Miller; J Blancato; J Hardy; K Gwinn-Hardy
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

4.  Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers.

Authors:  James Shorter; Susan Lindquist
Journal:  Science       Date:  2004-05-20       Impact factor: 47.728

5.  Dominant gain-of-function mutations in Hsp104p reveal crucial roles for the middle region.

Authors:  Eric C Schirmer; Oliver R Homann; Anthony S Kowal; Susan Lindquist
Journal:  Mol Biol Cell       Date:  2004-02-20       Impact factor: 4.138

6.  Phosphorylation of rat serine 105 or mouse threonine 217 in C/EBP beta is required for hepatocyte proliferation induced by TGF alpha.

Authors:  M Buck; V Poli; P van der Geer; M Chojkier; T Hunter
Journal:  Mol Cell       Date:  1999-12       Impact factor: 17.970

7.  Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans.

Authors:  S H Satyal; E Schmidt; K Kitagawa; N Sondheimer; S Lindquist; J M Kramer; R I Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

8.  Yeast cells provide insight into alpha-synuclein biology and pathobiology.

Authors:  Tiago Fleming Outeiro; Susan Lindquist
Journal:  Science       Date:  2003-12-05       Impact factor: 47.728

9.  Evidence for an unfolding/threading mechanism for protein disaggregation by Saccharomyces cerevisiae Hsp104.

Authors:  Ronnie Lum; Johnny M Tkach; Elizabeth Vierling; John R Glover
Journal:  J Biol Chem       Date:  2004-05-05       Impact factor: 5.157

10.  Phosphorylation of the vesicle-tethering protein p115 by a casein kinase II-like enzyme is required for Golgi reassembly from isolated mitotic fragments.

Authors:  A B Dirac-Svejstrup; J Shorter; M G Waters; G Warren
Journal:  J Cell Biol       Date:  2000-08-07       Impact factor: 10.539

View more
  22 in total

1.  Engineered protein disaggregases mitigate toxicity of aberrant prion-like fusion proteins underlying sarcoma.

Authors:  Jeremy J Ryan; Macy L Sprunger; Kayla Holthaus; James Shorter; Meredith E Jackrel
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

Review 2.  Spiraling in Control: Structures and Mechanisms of the Hsp104 Disaggregase.

Authors:  James Shorter; Daniel R Southworth
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-08-01       Impact factor: 10.005

3.  Hsp104 and Potentiated Variants Can Operate as Distinct Nonprocessive Translocases.

Authors:  Clarissa L Durie; JiaBei Lin; Nathaniel W Scull; Korrie L Mack; Meredith E Jackrel; Elizabeth A Sweeny; Laura M Castellano; James Shorter; Aaron L Lucius
Journal:  Biophys J       Date:  2019-04-05       Impact factor: 4.033

4.  Structural and mechanistic insights into Hsp104 function revealed by synchrotron X-ray footprinting.

Authors:  Elizabeth A Sweeny; Amber Tariq; Esin Gurpinar; Michelle S Go; Matthew A Sochor; Zhong-Yuan Kan; Leland Mayne; S Walter Englander; James Shorter
Journal:  J Biol Chem       Date:  2019-12-27       Impact factor: 5.157

5.  Therapeutic genetic variation revealed in diverse Hsp104 homologs.

Authors:  Katelyn Sweeney; Hanna Kim; Xiaohui Yan; Zachary M March; Laura M Castellano; Meredith E Jackrel; JiaBei Lin; Edward Chuang; Edward Gomes; Corey W Willicott; Karolina Michalska; Robert P Jedrzejczak; Andrzej Joachimiak; Kim A Caldwell; Guy A Caldwell; Ophir Shalem; James Shorter
Journal:  Elife       Date:  2020-12-15       Impact factor: 8.140

Review 6.  AAA+ Protein-Based Technologies to Counter Neurodegenerative Disease.

Authors:  Zachary M March; Korrie L Mack; James Shorter
Journal:  Biophys J       Date:  2019-03-22       Impact factor: 4.033

7.  Hydrogen exchange reveals Hsp104 architecture, structural dynamics, and energetics in physiological solution.

Authors:  Xiang Ye; Jiabei Lin; Leland Mayne; James Shorter; S Walter Englander
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-27       Impact factor: 11.205

Review 8.  The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future.

Authors:  Heike J Wobst; Korrie L Mack; Dean G Brown; Nicholas J Brandon; James Shorter
Journal:  Med Res Rev       Date:  2020-02-11       Impact factor: 12.944

9.  Structure of Calcarisporiella thermophila Hsp104 Disaggregase that Antagonizes Diverse Proteotoxic Misfolding Events.

Authors:  Karolina Michalska; Kaiming Zhang; Zachary M March; Catherine Hatzos-Skintges; Grigore Pintilie; Lance Bigelow; Laura M Castellano; Leann J Miles; Meredith E Jackrel; Edward Chuang; Robert Jedrzejczak; James Shorter; Wah Chiu; Andrzej Joachimiak
Journal:  Structure       Date:  2018-12-27       Impact factor: 5.006

Review 10.  Combating deleterious phase transitions in neurodegenerative disease.

Authors:  April L Darling; James Shorter
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2021-02-05       Impact factor: 4.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.